High-Dose Fluconazole for the Treatment of Cryptococcal Meningitis in HIV-Infected Individuals
Completed · Phase 1/Phase 2
Conditions studied: Cryptococcal Meningitis, HIV Infections
In brief
Cryptococcal meningitis (CM) is an infection of the membranes covering the brain and spinal cord, caused by the fungus Cryptococcus neoformans. CM most often affects people with compromised immune systems, like those with advanced HIV infection. This study explored the safety, tolerability, and therapeutic effect of a new treatment regimen with high-dose fluconazole for management of CM in HIV-infected patients.
Key facts
- Study ID
- NCT00885703
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 168
- Starts
- 2010-04-16
- Expected to finish
- 2017-01-12
- Last updated by the study team
- 2021-11-04
Who can join
Age: 16 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of Southern California CRS — Los Angeles, California, United States
- Byramjee Jeejeebhoy Medical College (BJMC) CRS — Pune, Maharashtra, India
- Kenya Medical Research Institute/Walter Reed Project Clinical Research Center (KEMRI/WRP) CRS — Kericho, Rift Valley, Kenya
- Moi University Clinical Research Center (MUCRC) CRS — Eldoret, Kenya
- San Miguel CRS — Lima, Peru
- Wits Helen Joseph Hospital CRS (Wits HJH CRS) — Johannesburg, Gauteng, South Africa
- Durban International Clinical Research Site CRS — Durban, KwaZulu-Natal, South Africa
- Chiang Mai University HIV Treatment (CMU HIV Treatment) CRS — Chiang Mai, Thailand
- Joint Clinical Research Centre (JCRC)/Kampala Clinical Research Site — Kampala, Uganda
- Parirenyatwa CRS — Harare, Zimbabwe
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.